<DOC>
	<DOCNO>NCT01373229</DOCNO>
	<brief_summary>In research study , lenalidomide ( also call Revlimid ) show response chronic lymphocytic leukemia ( CLL ) ; however , response usually partial response occur several month take study drug . It think add drug plerixafor ( also call Mozobil ) responses may improve and/or occur sooner . The main purpose study determine dose plerixafor safe use combination lenalidomide . The study also look response rate combination lenalidomide plerixafor effect study drug CLL cell .</brief_summary>
	<brief_title>Lenalidomide + Plerixafor Previously Treated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>The combination lenalidomide plerixafor evaluate single institution , open label clinical study subject relapse chronic lymphocytic leukemia ( CLL ) . The overall design phase 1 study include three treatment `` stage . '' Each subject receive lenalidomide 5mg mouth daily begin cycle 1 day 1 . If tolerate , dose increase 2.5mg every 7 day maximum dose 10mg mouth daily ( Stage 1 ) . Once subject stably maintain daily dose lenalidomide 10mg daily white blood cell ( WBC ) count &lt; 100.0 x 109 / L , take lenalidomide least 28 day , plerixafor add ( Stage 2 ) . In dose escalation phase , 4 different dos plerixafor combination lenalidomide study cohort 3 6 subject , follow standard `` 3 + 3 '' format : - Cohort 1 : plerixafor 0.24 mg/kg subcutaneous ( SC ) daily thrice weekly ( Mon , Wed , Fri ) - Cohort 2 : plerixafor 0.32 mg/kg SC daily thrice weekly ( Mon , Wed , Fri ) - Cohort 3 : plerixafor 0.42 mg/kg SC daily thrice weekly ( Mon , Wed , Fri ) - Cohort 4 : plerixafor 0.54 mg/kg SC daily thrice weekly ( Mon , Wed , Fri ) Plerixafor administer 3 week cycle ( day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 ) follow 1 week rest period . Lenalidomide dose continuous . An interim assessment response perform 4 cycle combination therapy : - Subjects achieve complete response ( CR ) National Cancer Institute ( NCI ) -96 criterion continue lenalidomide monotherapy ( plerixafor discontinue ) disease progression . - Subjects achieve partial response ( PR ) continue lenalidomide plerixafor . Additionally , rituximab 375mg/m2 add day 1 subsequent cycle begin cycle 5 , day 1 combination therapy . ( Stage 3 ) . Treatment combination lenalidomide plerixafor continue maximum 12 cycle combination therapy . Subjects may receive 8 dos rituximab concurrent lenalidomide plerixafor day 1 cycle . Subjects continue single agent lenalidomide disease progression . - Subjects stable disease may continue lenalidomide plerixafor discretion investigator subject . Rituximab 375 mg/m2 add day 1 subsequent cycle . Treatment , dose , schedule , duration subject achieve PR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Histologically confirm diagnosis chronic lymphocytic leukemia ( CLL ) Small lymphocytic lymphoma ( SLL ) establish National Cancer Institute ( NCI ) Working Group Response Criteria ( NCI 96 Criteria ) . Received one prior therapy CLL . Subjects must symptomatic disease require therapy define protocol . &gt; /= 4 week prior cancer therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . All study subject must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Prolymphocytic leukemia ( PLL ) . Richter 's ( large cell ) transformation . Prior allogeneic transplant within 12 month prior allogeneic transplant &gt; 12 month currently receive immunosuppressant . Active autoimmune hemolytic anemia . Central nervous system ( CNS ) involvement . Chronic enteral corticosteroid &gt; 10mg prednisone equivalent . Evidence laboratory tumor lysis syndrome ( TLS ) CairoBishop Definition Tumor Lysis Syndrome Use experimental drug therapy within 28 day baseline Major surgery within 28 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>